| III-01 Giulia Lestini Model-based optimal robust design in pharmacometrics Thursday 10:05-11:30 |
| III-02 Lia Liefaard Mixed effects modelling of dose-response cough count data Thursday 10:05-11:30 |
| III-03 Andreas Lindauer Time-to-seizure modeling of the antiepileptic drug lacosamide used in monotherapy Thursday 10:05-11:30 |
| III-04 Ling Xue Theory based PK-PD of S- and R-warfarin: influence of body size, composition and genotype Thursday 10:05-11:30 |
| III-05 Jesmin Lohy Das Population pharmacokinetic and pharmacodynamic (PK/PD) modelling of emerging artemisinin resistance in Southern Myanmar Thursday 10:05-11:30 |
| III-06 Kurt Long Identification of causal pathways determining the relationship between pathogen-specific infection and impaired growth among children < 59 months in Mirzapur, Bangladesh Thursday 10:05-11:30 |
| III-07 Dominik Lott Population pharmacokinetics of the selective S1P1 receptor modulator ponesimod Thursday 10:05-11:30 |
| III-08 Gaohua Lu A Novel Mechanistic Approach to Predict the Steady State Volume of Distribution (Vss) using the Fick-Nernst-Planck Equation Thursday 10:05-11:30 |
| III-09 Sreenath M Krishnan Population modeling of uni- and three- dimensional and density-based tumor measurements in gastro-intestinal stromal tumor (GIST) patients treated with imatinib Thursday 10:05-11:30 |
| III-10 Vincent Madelain Favipiravir pharmacokinetics in non-human primates: insights for future efficacy studies against hemorrhagic fever viruses Thursday 10:05-11:30 |
| III-11 Mats Magnusson Population PKPD Analysis of CD4 and ACR Response after SC Administration of Tregalizumab to Patients with Rheumatoid Arthritis Thursday 10:05-11:30 |
| III-12 Adedeji Majekodunmi Mechanistic modelling of naive CD4+ T cell homeostasis in HIV-infected children on anti-retroviral therapy Thursday 10:05-11:30 |
| III-13 Victor Mangas-Sanjuan Exploring Inter-study variability in the context of modeling unperturbed xenograft data Thursday 10:05-11:30 |
| III-14 Vikash Mansinghka BayesDB Marcro Indicator Explorer ensemble models for growth outcome country phenotyping Thursday 10:05-11:30 |
| III-15 Ben Margetts Modelling Severe Human Cytomegalovirus Infections in an Immunocompromised Paediatric Patient Population Thursday 10:05-11:30 |
| III-16 Amelie Marsot Population pharmacokinetic model of delta-9-tetrahydrocannabinol (THC) in cannabis occasional smokers Thursday 10:05-11:30 |
| III-17 Lisa Martial Population PK model and pharmacokinetic target attainment of micafungin in ICU patients Thursday 10:05-11:30 |
| III-18 Emma Martin Modelling based methods to account for dropout in xenograft experiments Thursday 10:05-11:30 |
| III-19 Jean-Marie Martinez Modelling and simulation of alirocumab – Part 1: Population pharmacokinetic analysis using a Michaelis-Menten approximation of the target-mediated drug disposition model Thursday 10:05-11:30 |
| III-20 Paolo Mazzei Population exposure-response modeling of oral nepadutant administration in infants with colic Thursday 10:05-11:30 |
| III-21 Litaty Céphanoée Mbatchi Pharmacokinetics modelling of temsirolimus and its active metabolite Thursday 10:05-11:30 |
| III-22 Johanna Melin Semi-mechanistic modelling of the nonlinear hydrocortisone pharmacokinetics to enable extrapolation into paediatric patients Thursday 10:05-11:30 |
| III-23 Evgeny Metelkin Development of immune responce template forsystems pharmacology modeling of immunotherapy in oncology Thursday 10:05-11:30 |
| III-24 Jonathan Mochel Pharmacodynamics of the renin-angiotensin aldosterone system and blood pressure in relation to food intake in dogs Thursday 10:05-11:30 |
| III-25 Shuhua Hu Use of interim analysis to improve efficiency of clinical trial simulations in treatment comparison trial design studies Thursday 10:05-11:30 |
| III-26 Pablo Morentin Gutierrez A population pharmacokinetic-pharmacodynamic model for AZD7687: Effects on plasma triacylglycerol after oral lipid tolerance test Thursday 10:05-11:30 |
| III-27 Michael Morimoto A quantitative physiologic model of the interaction of nutrition and infection in determining the energy available for growth Thursday 10:05-11:30 |
| III-28 Samer Mouksassi Primary microcephaly: do all roads lead to Rome? Thursday 10:05-11:30 |
| III-29 Morris Muliaditan Prediction of the exposure of anti-tuberculosis drugs in lung tissue: implications for dose selection Thursday 10:05-11:30 |
| III-30 Zufar Muliukov Modeling the effect of ranibizumab on central retinal thickness in patients with wet age-related macular degeneration Thursday 10:05-11:30 |
| III-31 Silke Gastine Population Pharmacokinetics of Voriconazole in pediatric cancer patients - assessing new dosing strategies Thursday 10:05-11:30 |
| III-32 C.J. Musante The International Society of Pharmacometrics’ Special Interest Group on Quantitative Systems Pharmacology: Developing a community and advancing a field Thursday 10:05-11:30 |
| III-33 Karin Nelander Longitudinal dose-response modelling as primary analysis of a clinical study Thursday 10:05-11:30 |
| III-34 Xavier Nicolas Modelling and simulation of alirocumab - Part 2: Population pharmacokinetic/pharmacodynamic analysis using an indirect response model to link drug concentrations with LDL-C Thursday 10:05-11:30 |
| III-35 Jaeseong Oh Simultaneous population pharmacokinetic analysis of VVZ-149 and its active metabolite in healthy volunteers Thursday 10:05-11:30 |
| III-36 Boram Ohk Population Pharmacokinetic modeling of Tacrolimus in Healthy Korean Subjects Thursday 10:05-11:30 |
| III-37 Andrés Olivares-Morales Combining population with physiologically-based pharmacokinetic (PBPK) models for oral drug absorption: Predicting the segmental bioavailability differences of R-oxybutynin and its main metabolite using a middle out approach. Thursday 10:05-11:30 |
| III-38 Per Olsson Gisleskog Predicting the effects of combining broadly neutralizing antibodies (bNabs) binding to different HIV viral epitopes Thursday 10:05-11:30 |
| III-39 Mohamed Omari Modelling of glucose-insulin metabolism and its effect on the estrous cycle in bovine Thursday 10:05-11:30 |
| III-40 Sean Oosterholt Model-based extrapolation and dosing recommendation for raxibacumab in children from birth to <18 years of age Thursday 10:05-11:30 |
| III-41 Stine Timmermann Ottesen Analysing the contribution to receptor occupancy from active metabolites Thursday 10:05-11:30 |
| III-42 - - Delineation of the treatment effect of methotrexate when used in combination therapy for rheumatoid arthritis Thursday 10:05-11:30 |
| III-43 Theodoros Papathanasiou Population modelling of the synergistic effects of morphine and gabapentin in the rat: a response surface approach Thursday 10:05-11:30 |
| III-44 Zinnia Parra-Guillen Pharmacokinetic analysis of midazolam and caffeine as probe drugs for cytochrome phenotyping in erlotinib treatment Thursday 10:05-11:30 |
| III-45 Sophie Peigné Optimal design in the analysis of a clinical study in paediatric population Thursday 10:05-11:30 |
| III-46 Nathalie Perdaems PK/PD modelling: a usefull tool to train people to better design in vivo chronic study in ob/ob mice Thursday 10:05-11:30 |
| III-47 Belén Pérez Solans Markov model for tumor shrinkage effects of combination therapy in non-metastatic gastric cancer patients Thursday 10:05-11:30 |
| III-48 Alejandro Pérez-Pitarch Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes Mellitus: Modelling Rate and Severity of Hypoglycemic Events Thursday 10:05-11:30 |
| III-49 Carlos Perez-Ruixo Population pharmacokinetics and antiviral efficacy in neonatal lambs: evidence of rapid maturation and auto-induction drug effect in metabolic clearance Thursday 10:05-11:30 |
| III-50 Caroline Petit Early phase dose-finding designs for bridging studies in pediatrics Thursday 10:05-11:30 |
| III-51 Séverine Petitprez Population pharmacokinetic meta-analysis of seven antiretroviral drugs Thursday 10:05-11:30 |
| III-52 Tatiana Petukhova Population PK modeling of RPH-104, novel optimized IL-1 beta trap, and assessment of the immunogenicity effect on pharmacokinetics Thursday 10:05-11:30 |
| III-53 Thomas Peyret A mechanistic maternal-fetal growth energy budget model Thursday 10:05-11:30 |
| III-54 Kimba Eddy Phongi Population Pharmacokinetics of the Novel Antimalarial OZ439 Thursday 10:05-11:30 |
| III-55 Chiara Piana A novel model-based methodology for the evaluation of abuse potential Thursday 10:05-11:30 |
| III-56 Philippe Pierrillas From mouse to human: comparison of interspecies translational strategies using integrative semi-mechanistic PK-PD models and PBPK-PD modeling to forecast efficacious clinical dose Thursday 10:05-11:30 |
| III-57 Teun Post Application of a Shiny Workflow in Cardiovascular Effects Evaluations Thursday 10:05-11:30 |
| III-58 Manuel Prado-Velasco Bridging the gap between open and specialized modelling tools in PBPK/PK/PD with PhysPK/EcosimPro modelling system: PBPK model of methotrexate and 6-mercaptopurine in humans with focus in reusability and multilevel modelling features Thursday 10:05-11:30 |
| III-59 Tim Preijers In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients Thursday 10:05-11:30 |
| III-60 Claire Pressiat Population pharmacokinetics of cotrimoxazole In West African HIV-infected children Thursday 10:05-11:30 |
| III-61 Angelica Quartino Comparisons of Multiple Exposure-Response Methodologies in Oncology Thursday 10:05-11:30 |
| III-62 Rachel Rose Development of a novel multi-compartment granuloma model to predict local drug distribution and its impact on pharmacodynamics and disease progression in tuberculosis. Thursday 10:05-11:30 |
| III-63 Christian Radke Development of a PBPK approach to predict the pharmacokinetics in patients with sepsis Thursday 10:05-11:30 |
| III-64 Christian Hove Claussen Automated modeling workflow with LaTeX: using the new Pfizer Report Tool Thursday 10:05-11:30 |
| III-65 Isabel Reinecke Changes in endogenous estradiol concentrations explain fluctuations in levonorgestrel (LNG) concentrations during continuous treatment with LNG releasing intravaginal rings Thursday 10:05-11:30 |
| III-66 Su-jin Rhee A population pharmacokinetic analysis of levetiracetam in patients with epilepsy Thursday 10:05-11:30 |
| III-67 Sophie Rhodes Previous BCG vaccination associated with variation in Mycobacterial-specific immune response: a modelling study Thursday 10:05-11:30 |
| III-68 Jakob Ribbing Predicting reductions in chronic obstructive pulmonary disease (COPD) exacerbations from FEV1 – A model-based meta-analysis of literature data from controlled randomized clinical trials Thursday 10:05-11:30 |
| III-69 Camille Riff First population pharmacokinetic model of lidocaine tumescent anaesthesia in women undergoing breast cancer surgery Thursday 10:05-11:30 |
| III-70 Clémence Rigaux Parasitemia clearance modeling following Ferroquine administration in P. Falciparum infected patients Thursday 10:05-11:30 |
| III-71 Christelle Rodrigues Population pharmacokinetics of oxcarbazepine and its 10-monohydroxy derivative in epileptic children Thursday 10:05-11:30 |
| III-72 Stefan Roepcke Model-based analysis of monkey PK and PD data of a therapeutic cell depleting human monoclonal antibody – Preparing for clinical trials Thursday 10:05-11:30 |
| III-73 Amit Roy Evaluating effectiveness of case-matching for exposure-response analysis Thursday 10:05-11:30 |
| III-74 Yue Ruan Bayesian hierarchical model of glucose-insulin regulation over 12-week home use of closed-loop insulin delivery Thursday 10:05-11:30 |
| III-75 Muhammad Waqas Sadiq Acute tolerance and rebound modelling with competitive interaction of mineralcorticoid driven urinary sodium excretion effects in the rat Thursday 10:05-11:30 |
| III-76 Richard Pugh Data Science & Big Data: An Opportunity or a threat for Pharmacometrics? Thursday 10:05-11:30 |
